2181 fundamentals
Key facts
Market capitalization—
Founded—
CEO—
Website—
About
Mabpharm Ltd. engages in the research, development, and manufacture of monoclonal antibody drugs for the treatment of cancer and autoimmune diseases. The company was founded on June 1, 2018 and is headquartered in Hong Kong.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
Dividends
Dividend yield, history and sustainability
No dividends
2181 has never paid dividends and has no current plans to do so.
Financial health
Financial position and solvency of the company